Literature DB >> 27769543

Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves' disease.

Giles Whalen1, Mary Sullivan2, Louise Maranda3, Robert Quinlan4, Anne Larkin4.   

Abstract

BACKGROUND: A short course of potassium iodide (SSKI) has been traditionally used to prepare patients with Graves' disease for thyroidectomy. The rationale for this treatment has evolved over time; from control of hyperthyroidism to facilitating surgery by making the gland less friable and bloody.
METHODS: Randomized trial of preoperative SSKI vs no SSKI to test whether that is true.
RESULTS: Mean estimated blood loss in the SSKI group (62 mL) was less than in the control group (162 mL) as was the median estimated blood loss (50 vs 140 mL). Mean (142 vs 162 minutes) and median (138 vs 150 minutes) operative times were also less in the SSKI arm. Subjective difficulty of operation was similar. Multivariable comparisons of groups with analysis of covariance showed the SSKI group suffered a mean blood loss 35% of the no treatment group (P = .036), the 9.2% decrease in Operating Room (OR) time between the SSKI group and the no treatment group was not statistically different (P = .464).
CONCLUSIONS: SSKI given before operation in patients with Graves' disease reduces blood loss during thyroidectomy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Grave's disease; Potassium iodide; Thyroidectomy

Mesh:

Substances:

Year:  2016        PMID: 27769543     DOI: 10.1016/j.amjsurg.2016.07.015

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Assessing American Thyroid Association Guidelines for Total Thyroidectomy in Graves' Disease.

Authors:  Siddique Akram; Dawn M Elfenbein; Herbert Chen; David F Schneider; Rebecca S Sippel
Journal:  J Surg Res       Date:  2019-08-08       Impact factor: 2.192

2.  Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty.

Authors:  Reese W Randle; Maria F Bates; Kristin L Long; Susan C Pitt; David F Schneider; Rebecca S Sippel
Journal:  Surgery       Date:  2017-11-03       Impact factor: 3.982

3.  Efficacy and safety of preoperative preparation with Lugol's iodine solution in euthyroid patients with Graves' disease (LIGRADIS Trial): Study protocol for a multicenter randomized trial.

Authors:  José Luis Muñoz de Nova; Guzmán Franch-Arcas; Gina Paola Mejía-Abril; María Eugenia Flores-Ruiz; Nuria Muñoz-Pérez; Elena Pintos-Sánchez; Francisco Javier Guadarrama González; Álvaro Valdés de Anca; Enrique Mercader-Cidoncha; Aitor de la Quintana-Basarrate; Irene Osorio-Silla; Susana Ros-López; Lander Gallego-Otaegui; Elena Santos-Molina; Concepción Martínez-Nieto; Elena Gamborino-Caramés; Mariano Artés-Caselles; Leyre Lorente-Poch; Maitane García-Carrillo; Pablo Moreno-Llorente; Consuelo Marín-Velarde; Joaquín Ortega-Serrano; Juan Manuel Martos-Martínez; Oscar Vidal-Pérez; Patricia Luengo-Pierrard; Jesús María Villar-Del-Moral
Journal:  Contemp Clin Trials Commun       Date:  2021-06-15

Review 4.  Lugol's solution and other iodide preparations: perspectives and research directions in Graves' disease.

Authors:  Jan Calissendorff; Henrik Falhammar
Journal:  Endocrine       Date:  2017-10-26       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.